nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2007 | Original Article

Somatostatin receptor scintigraphy using ^99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma

verfasst von: Rafał Czepczyński, Maria Gemma Parisella, Jerzy Kosowicz, Renata Mikołajczak, Katarzyna Ziemnicka, Maria Gryczyńska, Jerzy Sowiński, Alberto Signore

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Several new somatostatin analogues have been developed for the diagnosis and therapy of different tumours. Since somatostatin receptors are often over-expressed in medullary thyroid carcinoma (MTC), the aim of our study was to evaluate the utility of scintigraphy with the somatostatin analogue ^99mTc-EDDA/HYNIC-TOC in MTC in comparison with other diagnostic techniques.

Methods

Forty-five patients with MTC, aged 14–83 years, were investigated. Scintigraphy using ^99mTc-EDDA/HYNIC-TOC (Tektrotyd) was performed 2 and 4 h post injection of 740 MBq (20 mCi) of the tracer. Other imaging techniques were also applied and analysed in individual cases (ultrasonography, computed tomography, ^99mTc(V)-DMSA, ¹³¹I-MIBG, ^99mTc-MDP, ¹¹¹In-DTPA-octreotide and ¹⁸F-FDG-PET) and compared with ^99mTc-EDDA/HYNIC-TOC.

Results

In group 1 (eight patients before thyroidectomy), uptake of the tracer was found in the primary tumours. In group 2 (six patients with remission), a false positive result was found in one patient; in the remaining five patients, no pathological foci were visualised. In group 3 (31 patients with post-surgical hypercalcitoninaemia), scintigraphy was true positive in 23 patients (74.2%): uptake in the thyroid bed was found in five patients, in the lymph nodes in 18 and in bone metastases in four. Using ^99mTc-EDDA/HYNIC-TOC scintigraphy, the overall sensitivity was 79.5%, specificity 83.3%, accuracy 80.0%, positive predictive value 96.9% and negative predictive value 38.5%.

Conclusion

^99mTc-EDDA/HYNIC-TOC is clinically useful for scintigraphy in the follow-up of patients with MTC. It can be used in clinical practice for preoperative evaluation, for localisation of local recurrence or distant metastases and particularly for therapy decision making.

Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol 2005;89:122–9.PubMedCrossRef

Shoback D, Marcus R, Bikle D, Strewler G. Medullary thyroid carcinoma. In: Greenspan FS, Gardner DG, editors. Basic & clinical endocrinology. 6th ed. New York: Lange Medical Books/McGraw-Hill; 2001.

Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol 2003;4:339–47.PubMedCrossRef

Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88:2070–5.PubMedCrossRef

Schlumberger M, Pacini F. Medullary thyroid carcinoma. In: Schlumberger M, Pacini F, editors. Thyroid tumors. 2nd ed. Editions Nucleon, Paris; 2003.

Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029–34.PubMedCrossRef

Saller B, Moeller L, Gorges R, Janssen OE, Mann K. Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 2002;110:403–7.PubMedCrossRef

Wang Q, Takashima S, Fukuda H, Takayama F, Kobayashi S, Sone S. Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 2002;125:842–8.

Moll L, McEwan AJ. Iodine 131 MIBG scintigraphy of neuroendocrine tumours other than phaeochromocytoma and neuroblastoma. J Nucl Med 1987;28:978–88.

10.

Clarke SEM, Lazarus CR, Maisey MN. Experience in imaging medullary thyroid carcinoma using ^99mTc(V)-dimercaptosuccinic acid (DMSA). Henry Ford Hosp Med J 1989;37:167–8.PubMed

11.

Hilditch TE, Connell JMC, Elliott AT, Murray T, Reed NS. Poor results with ^99mTc-V-DMSA and ¹³¹iodine MIBG in the imaging of medullary thyroid carcinoma. J Nucl Med 1986;27:1150–3.PubMed

12.

Behr TM, Gratz S, Markus PM, Dunn RM, Hufner M, Schauer A, et al. Anticarcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997;80:2436–57.PubMedCrossRef

13.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-D-Phe¹]- and [¹²³I-Tyr³]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31.PubMedCrossRef

14.

Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912–6.PubMed

15.

Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new ^99mTc-tricine-HYNIC-D-Phe¹-Tyr³-octreotide: first results in patients and comparison with ¹¹¹In-DTPA-D-Phe¹-octreotide. Eur J Nucl Med 2000;27:628–37.PubMedCrossRef

16.

DeLellis RA, Rule AH, Spiler I, Nathanson L, Tashjian AH, Wolfe HJ. Calcitonin and carcinoembryogenic antigen as tumour markers in medullary thyroid carcinoma. Am J Clin Pathol 1978;70:587–94.PubMed

17.

Dörr U, Frank-Raue K, Raue F, Hehrmann R, Iser G, Bihl H. Localisation of recurrences from medullary thyroid carcinoma by somatostatin-receptor scintigraphy [abstract]. Eur J Nucl Med 1993;20:843.CrossRef

18.

Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with ¹¹¹In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59(5):565–73.CrossRef

19.

Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998;25:1277–83.PubMedCrossRef

20.

Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995;42:31–7.

21.

Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, et al. Comparison of ¹¹¹In-octreotide and ^99mTc(V)DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med 2001;26:683–8.PubMedCrossRef

22.

Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R.^99mTc-EDDA/HYNIC-TOC: a new ^99mTc-labelled radiopharmacuetical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with ¹¹¹In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318–25.PubMedCrossRef

23.

Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of ^99mTc-EDDA/HYNIC-TOC with ¹¹¹In-DTPAoctreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003;44:708–16.PubMed

24.

Plachcinska A, Mikolajczak R, Maecke HR, Mlodkowska E, Kunert-Radek J, Michalski A, et al. Clinical usefulness of ^99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. Eur J Nucl Med Mol Imaging 2003;30:1402–6.PubMedCrossRef

25.

Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, Maecke HR, Huszno B, Pach D, et al. ^99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123–33.PubMedCrossRef

26.

Maina T, Nock B, Nikilopoulou A, Sotiriou P, Loudos G, Maintas D, et al. ^99mTc-Demotate, a new ^99mTc-based [Tyr³]-octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 2002;29:742–53.PubMedCrossRef

27.

Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WA, van Gameren A, et al. ^99mTc-Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with ¹¹¹In-DOTA-tate. Eur J Nucl Med Mol Imaging 2006;33:831–40.PubMedCrossRef

28.

Parisella M, D'Alessandria C, van de Bossche B, Chianelli M, Ronga G, Papini E, et al. ^99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer Biother Radiopharm 2004;19:211–7.PubMedCrossRef

29.

Ohta H, Yamamoto K, Endo K. A new imaging agent for medullary thyroid cancer. J Nucl Med 1984;25:23–5.

30.

Verga V, Muratori F, Sacco G, Ban F, Libroia A. Role of ¹³¹Iodine MIBG and ^99mTc(V) DMSA in the diagnostic value of MTC. Henry Ford Hosp Med J 1989;37:175–7.PubMed

31.

Guerra UP, Pizzocara C, Terzi A. New tracers for imaging MTC. Nucl Med Commun 1989;10:285–95.PubMedCrossRef

32.

Wulfrank D, Schelstraete K, Small F, Charles F. Analogy between tumor uptake of technetium-99m-(V) dimercaptosuccinic acid (DMSA) and technetium-99m-MDP. Clin Nucl Med 1989;14:488–593.CrossRef

33.

Brandt-Mainz K, Muller SP, Gorges R. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27:490–6.PubMedCrossRef

34.

Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43:66–71.

35.

de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004;11:786–94.PubMedCrossRef

36.

Hoegerle S, Altehoefer C, Ghanem N. ¹⁸F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64–71.PubMedCrossRef

37.

Gourgiotis L, Sarlis NJ, Reynolds JC. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[¹⁸F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 2003;88:637–41.PubMedCrossRef

38.

Hofmann M, Maecke H, Corner R, Weckesser E, Schoffski P, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand ⁶⁸Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging 2001;28(12):1751–7.CrossRef

39.

Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of ¹¹¹In-pentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005;49(3):225–35.PubMed

40.

de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using ¹⁷⁷Lu- and ⁹⁰Y-labeled somatostatin analogs. J Nucl Med 2005;Suppl 1:13S–17S.

41.

Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with ⁹⁰Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 2006;26:703–7.PubMed

42.

Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with ¹⁷⁷Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with ⁹⁰Y-DOTATOC. J Nucl Med 2005;46:1310–6.PubMed

43.

Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, et al. Receptor radionuclide therapy with ⁹⁰Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004;19:65–71.PubMedCrossRef

Titel: Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma
verfasst von: Rafał Czepczyński
Maria Gemma Parisella
Jerzy Kosowicz
Renata Mikołajczak
Katarzyna Ziemnicka
Maria Gryczyńska
Jerzy Sowiński
Alberto Signore
Publikationsdatum: 01.10.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0479-1

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2007

Imaging biomarkers: from research to patient care—a shift in view

Habib Zaidi: Quantitative Analysis in Nuclear Medicine Imaging

PET probes and oncological surgery: a productive new marriage for nuclear medicine?

Performance of the new generation of whole-body PET/CT scanners: Discovery STE and Discovery VCT

Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study

Diagnosis of endoneural sciatic nerve invasion by uterine cervical epidermoid cancer using [18F]FDG-PET/CT